Best Practices for Intrathecal Baclofen Therapy: Troubleshooting

Michael Saulino, David J. Anderson, Jennifer Doble, Reza Farid, Fatma Gul, Peter Konrad, Aaron L. Boster

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Troubleshooting helps optimize intrathecal baclofen (ITB) therapy in cases of underdose, overdose, and infection. Methods: An expert panel of 21 multidisciplinary physicians currently managing >3200 ITB patients was convened, and using standard methodologies for guideline development, created an organized approach to troubleshooting ITB. They conducted a structured literature search that identified 263 peer-reviewed papers, and used results from an online survey of 42 physicians currently managing at least 25 ITB patients each. Results: The panel developed two algorithms. The first was for loss-of-efficacy and applies to patients with previously well-controlled hypertonia on a stable dosing regimen who have increased spasticity Evaluation includes a targeted history (onset, duration, course, exacerbating/relieving factors, medications, recent procedures), physical examination (neuromuscular, vital signs, mental status), radiologic/laboratory testing (catheter imaging, noxious stimuli, infection, rising CK levels), and pump telemetry (pump interrogation, reservoir volume). Rapidly progressing hypertonia with autonomic instability or hypotonia and somnolence require emergent care and perhaps hospitalization. The second algorithm was for emergent care and describes treatment of overdose or withdrawal, which requires immediate care in a monitored setting and restoration of ITB delivery. The previous dosing schedule can be used in withdrawal of short duration; 10–20 mg every six hours can be used in longer-duration withdrawal. Supportive care includes maintenance of airway, respiration, and circulation. Seizure prevention should be considered, along with pump reprogramming or interruption, cerebrospinal fluid drainage, and sequential lumbar punctures/drains. Physostigmine and flumazenil are not usually advised. Superficial infections can be treated with oral antibiotics, and deep infections with broad-spectrum IV antibiotics (e.g., cefazolin, clindamycin, vancomycin). Explantation is often required. A new pump can be implanted in a new site under IV antibiotic coverage. Conclusions: Orderly troubleshooting helps ensure patient safety.

Original languageEnglish (US)
Pages (from-to)632-641
Number of pages10
JournalNeuromodulation
Volume19
Issue number6
DOIs
StatePublished - Aug 1 2016

Fingerprint

Baclofen
Practice Guidelines
Anti-Bacterial Agents
Infection
Physicians
Therapeutics
Flumazenil
Cefazolin
Telemetry
Physostigmine
Muscle Hypotonia
Spinal Puncture
Clindamycin
Vital Signs
Vancomycin
Patient Safety
Physical Examination
Appointments and Schedules
Respiration
Seizures

Keywords

  • Baclofen/adverse effects
  • consensus
  • drug overdose
  • implantable/adverse effects
  • infusion pumps
  • intrathecal baclofen
  • substance withdrawal syndrome

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Saulino, M., Anderson, D. J., Doble, J., Farid, R., Gul, F., Konrad, P., & Boster, A. L. (2016). Best Practices for Intrathecal Baclofen Therapy: Troubleshooting. Neuromodulation, 19(6), 632-641. https://doi.org/10.1111/ner.12467

Best Practices for Intrathecal Baclofen Therapy : Troubleshooting. / Saulino, Michael; Anderson, David J.; Doble, Jennifer; Farid, Reza; Gul, Fatma; Konrad, Peter; Boster, Aaron L.

In: Neuromodulation, Vol. 19, No. 6, 01.08.2016, p. 632-641.

Research output: Contribution to journalArticle

Saulino, M, Anderson, DJ, Doble, J, Farid, R, Gul, F, Konrad, P & Boster, AL 2016, 'Best Practices for Intrathecal Baclofen Therapy: Troubleshooting', Neuromodulation, vol. 19, no. 6, pp. 632-641. https://doi.org/10.1111/ner.12467
Saulino M, Anderson DJ, Doble J, Farid R, Gul F, Konrad P et al. Best Practices for Intrathecal Baclofen Therapy: Troubleshooting. Neuromodulation. 2016 Aug 1;19(6):632-641. https://doi.org/10.1111/ner.12467
Saulino, Michael ; Anderson, David J. ; Doble, Jennifer ; Farid, Reza ; Gul, Fatma ; Konrad, Peter ; Boster, Aaron L. / Best Practices for Intrathecal Baclofen Therapy : Troubleshooting. In: Neuromodulation. 2016 ; Vol. 19, No. 6. pp. 632-641.
@article{8290e49bffdf4f9695e6cbfc54a38a46,
title = "Best Practices for Intrathecal Baclofen Therapy: Troubleshooting",
abstract = "Introduction: Troubleshooting helps optimize intrathecal baclofen (ITB) therapy in cases of underdose, overdose, and infection. Methods: An expert panel of 21 multidisciplinary physicians currently managing >3200 ITB patients was convened, and using standard methodologies for guideline development, created an organized approach to troubleshooting ITB. They conducted a structured literature search that identified 263 peer-reviewed papers, and used results from an online survey of 42 physicians currently managing at least 25 ITB patients each. Results: The panel developed two algorithms. The first was for loss-of-efficacy and applies to patients with previously well-controlled hypertonia on a stable dosing regimen who have increased spasticity Evaluation includes a targeted history (onset, duration, course, exacerbating/relieving factors, medications, recent procedures), physical examination (neuromuscular, vital signs, mental status), radiologic/laboratory testing (catheter imaging, noxious stimuli, infection, rising CK levels), and pump telemetry (pump interrogation, reservoir volume). Rapidly progressing hypertonia with autonomic instability or hypotonia and somnolence require emergent care and perhaps hospitalization. The second algorithm was for emergent care and describes treatment of overdose or withdrawal, which requires immediate care in a monitored setting and restoration of ITB delivery. The previous dosing schedule can be used in withdrawal of short duration; 10–20 mg every six hours can be used in longer-duration withdrawal. Supportive care includes maintenance of airway, respiration, and circulation. Seizure prevention should be considered, along with pump reprogramming or interruption, cerebrospinal fluid drainage, and sequential lumbar punctures/drains. Physostigmine and flumazenil are not usually advised. Superficial infections can be treated with oral antibiotics, and deep infections with broad-spectrum IV antibiotics (e.g., cefazolin, clindamycin, vancomycin). Explantation is often required. A new pump can be implanted in a new site under IV antibiotic coverage. Conclusions: Orderly troubleshooting helps ensure patient safety.",
keywords = "Baclofen/adverse effects, consensus, drug overdose, implantable/adverse effects, infusion pumps, intrathecal baclofen, substance withdrawal syndrome",
author = "Michael Saulino and Anderson, {David J.} and Jennifer Doble and Reza Farid and Fatma Gul and Peter Konrad and Boster, {Aaron L.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/ner.12467",
language = "English (US)",
volume = "19",
pages = "632--641",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Best Practices for Intrathecal Baclofen Therapy

T2 - Troubleshooting

AU - Saulino, Michael

AU - Anderson, David J.

AU - Doble, Jennifer

AU - Farid, Reza

AU - Gul, Fatma

AU - Konrad, Peter

AU - Boster, Aaron L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Introduction: Troubleshooting helps optimize intrathecal baclofen (ITB) therapy in cases of underdose, overdose, and infection. Methods: An expert panel of 21 multidisciplinary physicians currently managing >3200 ITB patients was convened, and using standard methodologies for guideline development, created an organized approach to troubleshooting ITB. They conducted a structured literature search that identified 263 peer-reviewed papers, and used results from an online survey of 42 physicians currently managing at least 25 ITB patients each. Results: The panel developed two algorithms. The first was for loss-of-efficacy and applies to patients with previously well-controlled hypertonia on a stable dosing regimen who have increased spasticity Evaluation includes a targeted history (onset, duration, course, exacerbating/relieving factors, medications, recent procedures), physical examination (neuromuscular, vital signs, mental status), radiologic/laboratory testing (catheter imaging, noxious stimuli, infection, rising CK levels), and pump telemetry (pump interrogation, reservoir volume). Rapidly progressing hypertonia with autonomic instability or hypotonia and somnolence require emergent care and perhaps hospitalization. The second algorithm was for emergent care and describes treatment of overdose or withdrawal, which requires immediate care in a monitored setting and restoration of ITB delivery. The previous dosing schedule can be used in withdrawal of short duration; 10–20 mg every six hours can be used in longer-duration withdrawal. Supportive care includes maintenance of airway, respiration, and circulation. Seizure prevention should be considered, along with pump reprogramming or interruption, cerebrospinal fluid drainage, and sequential lumbar punctures/drains. Physostigmine and flumazenil are not usually advised. Superficial infections can be treated with oral antibiotics, and deep infections with broad-spectrum IV antibiotics (e.g., cefazolin, clindamycin, vancomycin). Explantation is often required. A new pump can be implanted in a new site under IV antibiotic coverage. Conclusions: Orderly troubleshooting helps ensure patient safety.

AB - Introduction: Troubleshooting helps optimize intrathecal baclofen (ITB) therapy in cases of underdose, overdose, and infection. Methods: An expert panel of 21 multidisciplinary physicians currently managing >3200 ITB patients was convened, and using standard methodologies for guideline development, created an organized approach to troubleshooting ITB. They conducted a structured literature search that identified 263 peer-reviewed papers, and used results from an online survey of 42 physicians currently managing at least 25 ITB patients each. Results: The panel developed two algorithms. The first was for loss-of-efficacy and applies to patients with previously well-controlled hypertonia on a stable dosing regimen who have increased spasticity Evaluation includes a targeted history (onset, duration, course, exacerbating/relieving factors, medications, recent procedures), physical examination (neuromuscular, vital signs, mental status), radiologic/laboratory testing (catheter imaging, noxious stimuli, infection, rising CK levels), and pump telemetry (pump interrogation, reservoir volume). Rapidly progressing hypertonia with autonomic instability or hypotonia and somnolence require emergent care and perhaps hospitalization. The second algorithm was for emergent care and describes treatment of overdose or withdrawal, which requires immediate care in a monitored setting and restoration of ITB delivery. The previous dosing schedule can be used in withdrawal of short duration; 10–20 mg every six hours can be used in longer-duration withdrawal. Supportive care includes maintenance of airway, respiration, and circulation. Seizure prevention should be considered, along with pump reprogramming or interruption, cerebrospinal fluid drainage, and sequential lumbar punctures/drains. Physostigmine and flumazenil are not usually advised. Superficial infections can be treated with oral antibiotics, and deep infections with broad-spectrum IV antibiotics (e.g., cefazolin, clindamycin, vancomycin). Explantation is often required. A new pump can be implanted in a new site under IV antibiotic coverage. Conclusions: Orderly troubleshooting helps ensure patient safety.

KW - Baclofen/adverse effects

KW - consensus

KW - drug overdose

KW - implantable/adverse effects

KW - infusion pumps

KW - intrathecal baclofen

KW - substance withdrawal syndrome

UR - http://www.scopus.com/inward/record.url?scp=84981745051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981745051&partnerID=8YFLogxK

U2 - 10.1111/ner.12467

DO - 10.1111/ner.12467

M3 - Article

C2 - 27434299

AN - SCOPUS:84981745051

VL - 19

SP - 632

EP - 641

JO - Neuromodulation

JF - Neuromodulation

SN - 1094-7159

IS - 6

ER -